<DOC>
	<DOCNO>NCT02056782</DOCNO>
	<brief_summary>A Pilot Study ODSH Acute Myeloid Leukemia</brief_summary>
	<brief_title>A Pilot Study ODSH Acute Myeloid Leukemia</brief_title>
	<detailed_description>This open-label , multi-center , 10 patient pilot study anticipate 1 year enrollment period Primary Objectives : 1 . To evaluate safety tolerability ODSH patient Acute Myeloid Leukemia ( AML ) receive cytarabine idarubicin induction cytarabine consolidation chemotherapy . 2 . To determine whether preliminary evidence effect ODSH time transfusion-independent platelet recovery Acute Myeloid Leukemia ( AML ) patient receive cytarabine idarubicin induction cytarabine consolidation chemotherapy . Secondary Objectives : 1 . To determine whether preliminary evidence effect ODSH remission rate follow cytarabine idarubicin induction Acute Myeloid Leukemia ( AML ) patient . 2 . To determine whether preliminary evidence effect ODSH improve platelet nadir count Acute Myeloid Leukemia ( AML ) patient receive cytarabine idarubicin induction cytarabine consolidation chemotherapy . 3 . To determine whether preliminary evidence effect ODSH decrease number platelet transfusion Acute Myeloid Leukemia ( AML ) patient receive cytarabine idarubicin induction cytarabine consolidation chemotherapy . 4 . To determine whether preliminary evidence effect ODSH reduce overall side effect chemotherapy Acute Myeloid Leukemia ( AML ) patient receive cytarabine idarubicin induction cytarabine consolidation chemotherapy . Enrollment newly diagnose , previously untreated acute myeloid leukemia . Acute promyelocytic leukemia acute megakaryoblastic leukemia subtypes exclude . All patient receive standard induction chemotherapy cytarabine 100 mg/m2/day continuous intravenous infusion 24 hour daily 7 day ( D 1-7 ) plus idarubicin 12 mg/m2/day intravenous injection daily 3 day ( D 1-3 ) . For consolidation , patient younger 60 receive cytarabine dose 3 grams/m2 3 hour , every 12 hour day 1 , 3 , 5 . Induction cycle : ODSH 4 mg/kg IV bolus day 1 , 30 minute completion administration first dose idarubicin , ODSH 0.25 mg/kg/hour 24 hour daily continuous IV infusion day 1-7 . Consolidation cycle : ODSH 4 mg/kg IV bolus day 1 administer 30 minute completion infusion first dose cytarabine ODSH 0.25 mg/kg/hour 24 hour daily continuous IV infusion day 1-5 7 day induction cycle 5 day consolidation cycle</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Newly diagnose , previously untreated acute myeloid leukemia . Acute promyelocytic leukemia acute megakaryoblastic leukemia subtypes exclude No prior chemotherapy acute myeloid leukemia ; however , prior hydroxyurea control white blood cell count allow Age : ≥18 Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 Cardiac ejection fraction ≥ 50 % ( echocardiography MultiGated Acquisition Scan [ MUGA ] ) Adequate hepatic renal function ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , bilirubin creatinine &lt; 2.5 x upper normal limit ) . Able provide inform consent sign approve consent form conform federal institutional guideline . Patients acute promyelocytic leukemia Patients acute megakaryoblastic leukemia Patients Central Nervous System ( CNS ) leukemia Presence uncontrolled bleed Presence significant active infection uncontrolled judged investigator History severe congestive heart failure cardiac disease contraindicates use anthracyclines , include idarubicin Preexisting liver disease Renal insufficiency , , opinion investigator , might adversely affect schedule dose therapy cytarabine well management tumor lysis syndrome . Patients creatinine level ≥2 mg/dl eligible Use recreational drug history drug addiction , within prior 6 month Known history positive hepatitis B surface antigens hepatitis C virus ( HCV ) antibodies Known history positive test Human Immunodeficiency Virus ( HIV ) antibodies Psychiatric neurologic condition could compromise patient safety compliance , interfere ability give proper inform consent History active malignant disease within 5 year , cure basal cell carcinoma skin , cure situ carcinoma cervix , localized prostate cancer receive definitive therapy . Such prostate cancer patient receive hormonal therapy eligible Presence disseminate intravascular coagulation , confirm laboratory study demonstrate evidence increase thrombin generation ( decreased fibrinogen , prolong Prothrombin Time [ PT ] Partial Thromboplastin Time [ aPTT ] ) well increase fibrinolysis ( elevated Ddimer level ) Patients receive form anticoagulant therapy Presence know bleed disorder coagulation abnormality Treatment investigational agent within 7 day prior study entry . All prior toxicity resolve great Grade 1 ( exception alopecia ) Pregnant breastfeed patient Patient childbearing potential use adequate contraception Any condition require maintenance platelet count 50,000/μL high .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>ODSH</keyword>
	<keyword>ODSH-AML</keyword>
	<keyword>Cantex</keyword>
</DOC>